Abstract
Objective
To evaluate the predictive value of human epidermal growth factor receptor-2 (HER-2) and P53 in taxanebased and anthracycline-based neoadjuvant chemotherapy (NAC) in breast cancer.
Methods
Sixty-two patients with breast cancer were included in this study. Twenty-two patients were treated with taxane-based (taxane group) and 40 with anthracycline-based (anthracycline group). ER, PR, c-erbB2 and P53 were detected by immunohistochemistry staining before NAC, and Fluorescence In Situ Hybridization(FISH) was used to detect the HER-2 gene amplification for the cases with the expression of c-erbB2 protein as (++) or (+++). The efficacy of the regimens was evaluated a er NAC.
Results
In the anthracycline group, objective response (OR) was observed in 30 out of 40 patients (75%), whereas no response (NR) was observed in 10 patients (25%). In the taxane group, OR was observed in 15 patients out of 22 patients (68.2%), whereas NR was observed in 7 patients (31.8%). HER-2-negative status was correlated with a high OR in both taxane-based and anthracycline-based NAC (P = 0.023 and P = 0.029), whereas P53-negative status was correlated with high OR rate in anthracycline-based NAC (P = 0.041). The significant difference of the CR rates was observed between the patients took < 4 cycles and ≥ 4 cycles NAC (4.65% vs. 21.05%, P < 0.05).
Conclusion
The patients with HER-2 gene non-amplication may be sensitive to both taxane-based and anthracycline-based chemotherapy; the patients without P53 overexpression may suitable to select anthracycline-based chemotherapy; and proper increased NAC cycles may increase CR rates.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beriwal S, Schwartz GF, Komarnicky L, et al. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J 2006; 2: 159–164.
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 7: 2483–2493.
Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 2002; 9: 183–195.
Crown J, O’Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience. Oncologist 2004; 9: 24–32.
Petit T, Borel C, Ghnassia JP, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001; 7: 1577–1581.
Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40: 205–211.
Kariya S, Ogawa Y, Nishioka A, et al. Relationship between hormonal receptors, HER-2, P53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. Radiat Med 2005; 23: 189–194.
Kimura M, Sano M, Fujimori M, et al. Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes. Anticancer Res 2008; 28: 1239–1244.
Geisler S, Børresen-Dale AL, Johnsen H, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003; 9: 5582–5588.
Rahko E, Blanco G, Soini Y, et al. A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer 2003; 39: 447–453.
Bertheau P, Turpin E, Rickman DS, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007; 4: e90.
Bertheau P, Plassa F, Espié M, et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002; 360: 852–854.
Johnson KR, Fan W. Reduced expression of P53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil. Anticancer Res 2002; 22: 3197–3204.
Bao H, Yu D, Wang J, et al. Predictive value of serum anti-P53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients. Anticancer Drugs 2008; 19: 317–323.
Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and P53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50–56.
Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006; 97: 813–820
Reitsamer R, Peintinger F, Prokop E, et al. Pathological complete response rates comparing 3versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs 2005; 16: 867–870.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by a grant from the Ministry of Public Health Scientific Research Foundation of China (No.WKJ2007-3-001).
About this article
Cite this article
Wang, X., Yao, F., Liu, N. et al. Clinical implications of HER-2 and P53 in taxane-based and anthracycline-based neoadjuvant chemotherapy in breast cancer. Chin. J. Clin. Oncol. 5, 424–428 (2008). https://doi.org/10.1007/s11805-008-0424-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11805-008-0424-5